新加坡国立大学陈小元教授学术报告通知

Prof. Xiaoyuan (Shawn) Chen received his PhD in Chemistry from the University of Idaho (1999).After being a faculty at the University of Southern California, Stanford University and then Senior Investigator/Lab Chief at the National Institutes of Health, he is now Nasrat Muzayyin Chair Professor in Medicine and Technology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore. His current research focuses mainly on different forms of theranostics that can be clinically translatable. He has published over 1000 papers and numerous books (total citations > 130,000, H index 191 based on Google scholar). He was elected as AIMBE Fellow (2017) and SNMMI Fellow (2020), joined Advanced Materials Hall of Fame (2023), received JBN Trailblazer Award (2023), SNMMI Michael J. Welch Award (2019), ACS Bioconjugate Chemistry Lecturer A1ward (2016), NIH Director’s Award (2014), NIBIB Mentor Award (2012). He is also the Past President of Chinese American Society of Nuclear Medicine and Molecular Imaging (CASNMMI), Past President of the Radiopharmaceutical Science Council (RPSC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), and Past President of the Chinese American Society of Nanomedicine and Nanobiotechnology (CASNN).

报告摘要：

Theranostics, the combination of ther(apy) and (diag)nostics, aims to develop molecular diagnostic tests and targeted therapeutics with the goals of individualizing treatment by targeting therapy to an individual's specific disease subtype and genetic profile. It can be diagnosis followed by therapy to stratify patients who will likely respond to a given treatment. It can also be therapy followed by diagnosis to monitor early response to treatment and predict treatment efficacy. It is also possible that diagnostics and therapeutics are co-developed (sonotheranostics, immunotheranostics, magnetotheranostics, optotheranostics, radiotheranostics, etc.). This talk will highlight the form of radiotheranostics, which uses radionuclides for the paired imaging and therapy agents. The imaging component “sees” the lesions, and the therapy agent “treats” the same lesions. Two prominent cancer targets fibroblast activation protein (FAP) and prostate specific membrane antigen (PSMA) will be highlighted with preclinical and initial clinical experience will be described in details.

欢迎广大师生届时前往交流！

多靶标天然药物全国重点实验室

青年创新学者联合会

高端药物制剂与材料研究中心

2023年11月5日